News
EMA Grants Axelar Orphan Drug Designation for AXL1717 for the Treatment of Glioma
25 July 2017
Axelar AB today announced that the European Medicines Agency (EMA) has granted orphan designation to Axelar's drug candidate AXL1717 for the treatment of glioma. The EMA's orphan designation program is intended to encourage the development of …
Axelar attended 2017 BIO International Convention in San Diego, USA
26 June 2017
Axelar AB attended the 2017 BIO International Convention June 19-22 in San Diego, USA to meet with potential partners and investors. During the convention there were 16 123 attendees from 74 countries and 3 500 participating organizations took part …
Axelar attends BIO-Europe Spring partnering conference in Stockholm, Sweden
4 April 2016
Axelar AB will attend when the tenth annual BIO-Europe Spring conference Stockholm, Sweden on April 4–6, 2016 to meet with potential partners and investors. This is a partnering conference for the biotechnology industry and the conference annually …